Mipsy: Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial

Sponsor
Psychiatry Roskilde (Industry)
Overall Status
Unknown status
CT.gov ID
NCT01070134
Collaborator
(none)
84
1
2
17.9
4.7

Study Details

Study Description

Brief Summary

Background:

According to the WHO, major depressive disorder is the second largest healthcare problem worldwide in terms of disability caused by illness. It afflicts an estimated 17% of individuals during their lifetimes at tremendous costs. A number of depressive patients are treated with antidepressant medication. The efficacy of antidepressant medication has been studied in a number of systematic reviews, and in recent years some of these reviews have shown that the efficacy is questionable for many patients. So are there other effective treatments for this serious illness?

Cognitive- and psychodynamic therapies are probably both significantly more effective for depression than no treatment, but only limited comparisons have been made between the two interventions. A Cochrane review shows that cognitive therapy has a preventive effect against recurrent depression, and that this effect may surpass the preventive effect of antidepressant medication. Mindfulness training may be an effective technique in preventing relapse in patients who have had at least 3 previous depressive episodes. But efficacy in treating currently depressed patients has not been studied.

Objective To perform a randomised clinical trial with blinded assessment of efficacy variables in order to study the effects of mindfulness based behavioral therapy (cognitive therapy and mindfulness) versus psychodynamic therapy in depressive patients.

Methods

A randomised clinical trial of 84 consecutive patients diagnosed with major depressive disorder, referred to the day clinic, Roskilde psychiatric services. The patients will be randomised to one of two interventions:

  1. MIBT (mindfulness-based behavioural therapy)

  2. PT (psychodynamic therapy)

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness-based Behavioural Therapy (MIBT)
  • Behavioral: PT (psychodynamic therapy)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial
Study Start Date :
Feb 1, 2010
Anticipated Primary Completion Date :
Aug 1, 2011
Anticipated Study Completion Date :
Aug 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness-based Behavioural Therapy (MIBT)

Behavioral: Mindfulness-based Behavioural Therapy (MIBT)
The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours). The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness.

Active Comparator: PT (psychodynamic therapy)

Behavioral: PT (psychodynamic therapy)
The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours). The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions.

Outcome Measures

Primary Outcome Measures

  1. 17 item Hamilton rating scale for depression (score at the end of 18 weeks of day- treatment) [0 weeks, 18 weeks, and 1 year]

Secondary Outcome Measures

  1. SCL-90-R (GSI score at the end of 18 weeks of day- treatment) [0 weeks, 9 weeks, 18 weeks, and 1 year]

  2. The proportion of patients who achieve remission (Hamilton score < 8). [0 weeks, 18 weeks, and 1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged 18 to 65 years

  2. Major depressive disorder (SCID I).

  3. BDI II > 13.

  4. Written informed consent.

Exclusion Criteria:
  1. Current psychosis, diagnosis of schizophrenia or schizotypal personality disorder (DSM IV-TR).

  2. Alcohol or substance abuse judged to require treatment in preference to depression (assessed during patient conference).

  3. Commenced or changed psychopharmacological treatment less than six weeks before randomisation.

  4. Pregnancy.

  5. No written informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The day clinic for treatment of non-psychotic disorders (Roskilde Psychiatry) Roskilde Zeeland Denmark 4000

Sponsors and Collaborators

  • Psychiatry Roskilde

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01070134
Other Study ID Numbers:
  • Mipsy trial
First Posted:
Feb 17, 2010
Last Update Posted:
Jun 8, 2011
Last Verified:
Feb 1, 2010

Study Results

No Results Posted as of Jun 8, 2011